Atherosclerotic Cardiovascular Disease Clinical Trials

14 recruiting

Atherosclerotic Cardiovascular Disease Trials at a Glance

22 actively recruiting trials for atherosclerotic cardiovascular disease are listed on ClinicalTrialsFinder across 6 cities in 43 countries. The largest study group is Not Applicable with 7 trials, with the heaviest enrollment activity in Las Vegas, Miami, and Houston. Lead sponsors running atherosclerotic cardiovascular disease studies include Novartis Pharmaceuticals, Amgen, and China National Center for Cardiovascular Diseases.

Browse atherosclerotic cardiovascular disease trials by phase

Treatments under study

About Atherosclerotic Cardiovascular Disease Clinical Trials

Looking for clinical trials for Atherosclerotic Cardiovascular Disease? There are currently 14 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Atherosclerotic Cardiovascular Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Atherosclerotic Cardiovascular Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 22 trials

Recruiting
Phase 2Phase 3

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis

Atherosclerotic Cardiovascular Disease
CSL Behring2,310 enrolled542 locationsNCT05485961
Recruiting
Phase 3

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

ObesityOverweightAtherosclerotic Cardiovascular Disease
Amgen12,800 enrolled759 locationsNCT07037433
Recruiting
Phase 3

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

Atherosclerotic Cardiovascular Disease (ASCVD)Elevated Lp(a)
Eli Lilly and Company10,450 enrolled751 locationsNCT07157774
Recruiting

Aspirin 50 mg vs. 100 mg in Elderly Cardiovascular Disease Patients

Cardiovascular DiseasesAtherosclerotic Cardiovascular Disease (ASCVD)Secondary Prevention
Peking University First Hospital5,448 enrolled1 locationNCT07542860
Recruiting
Phase 3

Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

Atherosclerotic Cardiovascular Disease (ASCVD)
Novartis Pharmaceuticals340 enrolled92 locationsNCT06813911
Recruiting
Phase 3

Pelacarsen Roll-over Extension Program

Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals599 enrolled97 locationsNCT06875973
Recruiting
Phase 1Phase 2

TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD

Endothelial DysfunctionAtherosclerotic Cardiovascular Diseases
Hudson Biotech80 enrolled1 locationNCT07487363
Recruiting
Not Applicable

Study of the Determinants of Coronary Atherosclerosis in Familial Hypercholesterolemia (ATHERO-FH Study)

Atherosclerotic Cardiovascular Disease (ASCVD)Familial Hypercholesterolemias
Nantes University Hospital600 enrolled9 locationsNCT06960902
Recruiting
Early Phase 1

Placebo-controlled Study of Single and Multiple Ascending Doses of UDP-003 in Healthy Human Participants and Patients

Atherosclerotic Cardiovascular DiseaseAcute Coronary Syndromes
Cyclarity Therapeutics, Inc.84 enrolled1 locationNCT06813339
Recruiting

A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease

Major Cardiovascular EventEstablished Atherosclerotic Cardiovascular Disease
Amgen7,000 enrolled90 locationsNCT06295679
Recruiting
Not Applicable

A Tailored, Optimised, and Person-centred Programme to Promote Lifestyle Modification in People With Metabolic Syndrome

Metabolic SyndromePrimary Prevention of Atherosclerotic Cardiovascular Disease
The University of Hong Kong152 enrolled1 locationNCT06793930
Recruiting
Phase 4

Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia

Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals326 enrolled1 locationNCT07034690
Recruiting
Phase 3

Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease

Atherosclerotic Cardiovascular Disease (ASCVD)Atherothrombotic Diseases
Hospital do Coracao7,713 enrolled13 locationsNCT06930885
Recruiting
Phase 1

Fish Oil, Metformin and Heart Health in PCOS

Cardiovascular DiseasePCOSAtherosclerotic Plaque+2 more
University of Alberta146 enrolled3 locationsNCT06424860
Recruiting
Not Applicable

Polygenic Risk Score Implementation and Stratification for Managing Blood Pressure

HypertensionAtherosclerotic Cardiovascular Disease
University of Alabama at Birmingham300 enrolled1 locationNCT06962488
Recruiting

Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia

Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals2,382 enrolled20 locationsNCT06858332
Recruiting
Not Applicable

A Pragmatic INitiative for LDL-C Management by a CLinical Pharmacist-Led Team Among Atherosclerotic CardiovascUlar DisEase Patients

Atherosclerotic Cardiovascular Disease
Intermountain Health Care, Inc.400 enrolled1 locationNCT06571162
Recruiting
Phase 3

The Prevent Coronary Artery Disease Trial

Atherosclerotic Cardiovascular Disease
Icahn School of Medicine at Mount Sinai1,600 enrolled1 locationNCT06494501
Recruiting
Not Applicable

Coated or Chewable Aspirin and a Hybrid Strategy to Mitigate Adverse Effects of Air Pollution in Stable Atherosclerotic Disease

Peripheral Arterial DiseaseCoronary Artery DiseaseIschemic Stroke+3 more
Rajaie Cardiovascular Medical and Research Center3,000 enrolled1 locationNCT06541691
Recruiting
Not Applicable

Effectiveness of Decision Support for Cardiovascular Risk Management in People With Cardiovascular Disease

Atherosclerotic Cardiovascular Diseases
dr.Frank L.J. Visseren1,200 enrolled8 locationsNCT06871514